PSMA and PSA level

Abstract: Prostate cancer (PCa), the most common cancer in men, is the second leading cause of cancer deaths among men. The clinical management of PCa is challenging due to the variable clinical and pathologic behavior of the disease. Thus, the treatment of PCa should be optimized and specific to each patient in order to improve their outcomes. In recent years, there has been increasing focus on prostate-specific membrane antigen (PSMA) as a target for both imaging and therapy. PSMA is a type II integral membrane glycoprotein (100–120 kDa), with an intracellular component, a transmembrane component, and a large extracellular domain. PSMA is highly expressed by all PCa, and its expression increases with tumor aggressiveness, metastatic disease and disease recurrence. PSMA represents an excellent target for both imaging and therapy of PCa. During the last two decades, many efforts have been undertaken to develop high affinity PSMA ligands for both imaging and therapy. This image and treat strategy has the potential to become a milestone in the management of PCa patient. The purpose of this review is to highlight the most important developments of PSMA PET imaging reported in the past year as well as a correlation between PSA level and PSMA findings.

کلیدواژه ها:

68Ga-PSMA ، PET/CT ، Prostate cancer